DBV Technologies (DBVT) Income from Continuing Operations (2020 - 2026)
DBV Technologies (DBVT) posted Income from Continuing Operations of 50400000.0 for Q2 2026, down 5.88% sequentially from 47600000.0 in Q1 2026, and down 20.29% YoY from 63226347.31 in Q2 2025.
Powered by 
Analysis
DBV Technologies (DBVT) Income from Continuing Operations (2020 - 2026) Analysis & Trends
DBV Technologies has reported Income from Continuing Operations for 7 years, with the latest figure at 50400000.0 in Q2 2026.
- Quarterly Income from Continuing Operations fell 20.29% year-over-year to 50400000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 175993000.0 (down 43.72% YoY) and the FY2025 annual result came in at 146947000.0, down 28.99% from the prior year.
- Income from Continuing Operations slipped to 50400000.0 in Q2 2026 per DBVT's latest filing, from 47600000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 11186000.0 in Q4 2023 and troughed at 50400000.0 in Q2 2026.
- A 5-year average of 29328333.33 and a median of 27222500.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations slumped 187.02% in 2022, then surged 71.49% in 2023.
- Over 5 years, Income from Continuing Operations stood at 39241000.0 in 2022, then soared by 71.49% to 11186000.0 in 2023, then sank by 105.75% to 23015000.0 in 2024, then sank by 94.78% to 44829000.0 in 2025, then fell by 12.43% to 50400000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 50400000.0, 47600000.0, and 44829000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | DBV Technologies | 5.86 Bn | 5.68 Bn | - | -50.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.40 Mn |
| Mar 31, 2026 | -47.60 Mn |
| Dec 31, 2025 | -44.83 Mn |
| Sep 30, 2025 | -33.16 Mn |
| Jun 30, 2025 | -41.90 Mn |
| Mar 31, 2025 | -27.10 Mn |
| Dec 31, 2024 | -23.02 Mn |
| Sep 30, 2024 | -30.44 Mn |
| Jun 30, 2024 | -33.12 Mn |
| Mar 31, 2024 | -27.35 Mn |
| Dec 31, 2023 | -11.19 Mn |
| Sep 30, 2023 | -16.74 Mn |
| Jun 30, 2023 | -24.24 Mn |
| Mar 31, 2023 | -20.56 Mn |
| Dec 31, 2022 | -39.24 Mn |
| Sep 30, 2022 | -17.29 Mn |
| Jun 30, 2022 | -23.04 Mn |
| Mar 31, 2022 | -16.71 Mn |
| Dec 31, 2021 | -13.67 Mn |
| Sep 30, 2021 | -24.03 Mn |